Tanshinone IIA normalized Hepatocellular Carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tanshinone IIA normalized Hepatocellular Carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1
Authors
Keywords
-
Journal
PHYTOMEDICINE
Volume -, Issue -, Pages 155191
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.phymed.2023.155191
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
- (2023) Matteo Santoni et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
- (2022) Matteo Santoni et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
- (2022) Yan Tie et al. Journal of Hematology & Oncology
- Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy
- (2022) Cheng Qian et al. PHARMACOLOGICAL RESEARCH
- High endothelial venules as potential gateways for therapeutics
- (2022) Bilal Hussain et al. TRENDS IN IMMUNOLOGY
- A theranostic metallodrug modulates immunovascular crosstalk to combat immunosuppressive liver cancer
- (2022) Ying Luo et al. Acta Biomaterialia
- Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
- (2021) Ashraf Ul Kabir et al. Science Translational Medicine
- ELTD1—An Emerging Silent Actor in Cancer Drama Play
- (2021) Ani-Simona Sevastre et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer
- (2021) Yu Zhang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
- (2021) Alessandro Rizzo et al. Immunotherapy
- ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma
- (2021) Hua Huang et al. NEURO-ONCOLOGY
- Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach
- (2021) Ali N. Chamseddine et al. PHARMACOLOGY & THERAPEUTICS
- Improved Immunotherapy Efficacy by Vascular Modulation
- (2021) Emma L. Newport et al. Cancers
- ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
- (2020) Dong-Hoon Yeom et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2019) Miguel F. Sanmamed et al. CELL
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities
- (2019) Chen Lu et al. Molecular Cancer
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- ELTD1 Function in Hepatocellular Carcinoma is Carcinoma-Associated Fibroblast-Dependent
- (2018) Anna Kan et al. Journal of Cancer
- Tanshinone II-A Inhibits Invasion and Metastasis of Human Hepatocellular Carcinoma Cells in Vitro and in Vivo
- (2018) Xu Yuxian et al. TUMORI
- Nivolumab for the treatment of hepatocellular carcinoma
- (2018) Fabian Finkelmeier et al. Expert Review of Anticancer Therapy
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo
- (2017) Hsiang-Ping Lee et al. Oncotarget
- The effects of tanshinone IIA on hypoxia/reoxygenation-induced myocardial microvascular endothelial cell apoptosis in rats via the JAK2/STAT3 signaling pathway
- (2016) Zhen-Tian Cui et al. BIOMEDICINE & PHARMACOTHERAPY
- Targeted Delivery of Tanshinone IIA-Conjugated mPEG-PLGA-PLL-cRGD Nanoparticles to Hepatocellular Carcinoma
- (2014) Yan Wang et al. Journal of Biomedical Nanotechnology
- Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells
- (2014) YINGYING XING et al. ONCOLOGY REPORTS
- Mechanism of reversal of high glucose-induced endothelial nitric oxide synthase uncoupling by tanshinone IIA in human endothelial cell line EA.hy926
- (2012) Zhi-Wei Zhou et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization
- (2012) Wen-Quan Wang et al. Journal of Hematology & Oncology
- Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells
- (2011) Ming-Yen Tsai et al. CANCER LETTERS
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started